Dr. Harold Katz, LLC also known as "The Breath company" developed TheraBreath multisymptom probiotics and oral care probiotics "to actively attack the bacteria that is responsible for tooth decay, cavities, acid erosion, bleeding and sensitive gums, plaque, tooth staining, and other germ-related oral care maladies". These probiotics were developed specifically for colonizing the tongue, mouth, and throat.
M18 and K12 strains of a beneficial bacteria called Streptococcus Salivarius which normally occurs in the mouth, throat and nose. These strains produce bacterocin like inhibitory subtances (BLIS) proteinaceous compounds (BLIS) capable of inhibiting the growth of similar bacterial strains.
Dr. Harold Katz, LLC also known as "The Breath company" developed TheraBreath multisymptom probiotics and oral care probiotics "to actively attack the bacteria that is responsible for tooth decay, cavities, acid erosion, bleeding and sensitive gums, plaque, tooth staining, and other germ-related oral care maladies". These probiotics were developed specifically for colonizing the tongue, mouth, and throat.
Comments
High-potency probiotic with 450 billion live bacteria per packet. Intended for the dietary management of patients with ulcerative colitis (UC), an Ileal Pouch (IP), and irritable bowel syndrome (IBS) Published studies suggest that daily ingestion of VSL#3 DS can aid in the dietary management of Ulcerative Colitis (UC) in both adults and pediatric patients. These studies have also demonstrated that VSL#3 DS can be utilized along with standard pharmaceutical UC therapies such as 5-ASA, immunosuppressants, immunomodulatory drugs and steroids. VSL#3 DS sachets contain Lactic acid bacteria, maltose, silicon dioxide, non-fat dry milk. The lactic acid bacteria in VSL#3 DS are grown in culture mediums that use non-fat dry milk as a fermentation nutrient. Species include:
Bifidobacterium adolescentis are bacterial species of Bifidobacteria. It includes several strains such as ATCC15703, DSM 20087, DSM 24849, JCM 15918, etc. This species are members of the normal intestinal tract and appendix, dental caries and vagina flora of healthy humans. The population of these bacteria in the colon appears to be relatively stable until late adulthood when it appears to decline. Numbers are higher in elderly and younger adults (2013), in individuals consuming more resistant starch RS4 and inulin (2013), and lower in long term asthma (2013) Bifidobacterium adolescentis has antiviral anticancer activity (2012) and is used in probiotics and "therapeutic milk", often mixed with Streptococcus thermophilus. It synthesizes various B vitamins including thiamin (B1), pyridoxine (B6), folic acid (B9), nicotine, cyanocobalamin (B12), ascorbic acid (Vitamin C), biotin, and riboflavin. Dietary consumption of selected bifidobacteria strains, especially B. adolescentis, in a yogurt-based diet may offer benefit to elderly individuals to prevent some of the harmful effects of immunosenescence (El Bakry, 2013). B. adolescentis could decrease immunity to opportunistic pathogens such as Bacteroides thetaiotaomicron, the second most common infectious anaerobic gram-negative bacteria, frequently associated with peritonitis, septicemia, and wound infections. Firmicute (Clostridia) bacteria, normal inhabitant of human gut, associated with reduction in body weight. Species include C. minuta, C. timonensis and C. massiliensis. Christensenella minuta's presence in human body is most strongly affected by our genes (40% probability that people with genes predisposing to this microbe will have it). Firmicutes, Lactobacilli bacteria that naturally inhabits digestive tract (aka alimentary canal: esophagus, stomach, and intestines) and is used as probiotics When added to dog faecal cultures, LA4 reduced enterococci and increased lactobacilli counts throughout the study. In mice it induced healthful immune responses that reduce chronic inflammation associated to Mycobacterium avium infection. Lactobacillus gasseri is an anaerobic, gram-positive Lactobacillus (lactic acid) bacterium. It is a rod shaped and of the non-spore-forming type and is typically found in the gastrointestinal tracts of humans and animals due to its largely fermentative function. It also has protective functions (producing hydrogen peroxide) in the vagina. L. gasseri produces gassericin A, a bacteriocin, toxic to E.coli and a wide range of soil-borne bacteria Lactobacillus gasseri strain SBT2055 (LG2055) showed its abilities to reduce stomach fat (abdominal adiposity) even at doses as low as the order of 10(8) cfu/d. Constant consumption might be needed to maintain the effect. Lactobacillus gasseri BNR17 isolated from human breast milk can inhibit obesity and diabetic activities in the human body, but weight reduction after taking this probiotic is very small. Lactobacillus gasseri OLL2716 proved effective in both suppressing H. pylori colonization of the stomach and reducing gastric mucosal inflammation. L. gasseri OLL2716 strain contained in a yogurt drink can colonize the gastric mucus layer in infected patients. It does so by coccoid conversion of H. pylori (manifestation of their death) due to dl-lactic acid. Firmicutes, Lactobacilli bacteria that naturally inhabits the gut and is used as probiotics. L. reuteri produces antimicrobial substabces reuterin, reutericin and reutericyclin. It is found in breast milk and many probiotic yogurts. L. reuteri is used to alleviate rotavirus-induced diarrhea, especially in children, food-borne pathogens and protects against many common infections. It can ameliorate gingivitis and fight tooth decay. L. reuteri was shown to improve autistic social behavior (like spending less time with peers) but did not seem to help with anxiety. It may also lower low density cholesterol (LDL) levels. Probiotic made by Novartis but only available in Europe (Omniflora N in Germany, Omniflora Akut in Switzerland) Areas of application: Traditionally used as a mildly effective remedy to support bowel function, relive constipation and diarrhea. flatulence, bloating, constipation and abdominal pain, increased susceptibility to infections. Active ingredients: Omniflora N: lactic acid bacteria (Lactobacillus grasseri, Bifidobacterium longum); Omniflora Akut: Saccharomyces Boulardii Note: Contains Sucrose (sugar) and lactose. species of spherical, gram-positive bacteria Streptococci (from phylum Firmicutes) that forms chains and colonizes the mouth and upper respiratory tract of humans just a few hours after birth, making further exposure to the bacteria harmless in most circumstances. It is considered to be a "good" oral bacteria fighting bad odor and disease-causing species yet, if it gets into bloodstream (what, fortunately, rarely happens), it could be associated with sepsis in people with neutropenia (a deficiency in white blood cells). Streptococcus salivarius secretes a glucosltransferase (Gtf) which forms a glucan from sucrose and it uses sucrose (but not glucose) to build a capsule around itself. This bacteria can ferment the glucose yielding lactic acid. S. salivarius is also known to secrete an enzyme called urease. Urease can catalyze the hydrolysis of urea to ammonia and carbon dioxide Streptococcus uberis is an environmental cocci bacterium responsible for infection of the breast tissue in bovines and helpful in replacing harmful oral bacteria in humans. It is occasionally described as a human pathogen, though in most cases it happened because it was mistaken for Enterococcus faecium. Streptococcus uberis is Gram-positive bacterium. It's cell wall structure is similar to Staphylococcus species., as well as streptococci such as S. agalactiae and S. dysgalactiae. S. uberis is the most common Streptococcus species isolated from cases of mastitis. The control of S. uberis in bovines includes maintenance of a clean and dry housing environment and implementation of proper milking procedures. Probiotics with Streptococcus uberis KJ2 along with Streptococcus oralis KJ3, and Streptococcus rattus JH145 were studied after scaling and root planing (SRP), but no differences were detected when comparing the adjunctive use of a placebo or the investigated streptococci containing probiotic tablet after SRP (ClinicalTrials.gov Identifier: NCT02403960), except that the % of sites with plaque that were significantly lower in the probiotic group than in the control group at the 24-week evaluation. In addition, at the 12-week time point, the salivary Prevotella intermedia counts were significantly lower in the probiotic group. In another clinical trial, both EvoraKids and PerioBalance (containing Streptococcus uberis KJ2) affected the Caries Risk Test results by significantly decreasing the number of S. mutans and lactobacilli present in the salivary samples. |
Categories
All
|